Decitabine是一种有效的DNA甲基化抑制剂,作用于HL-60和KG1a细胞时,IC50分别为100 ng/mL和1 ng/mL。
Decitabine is a kind of deoxycytidine analog and an inducer of cellular differentiation. It is able to incorporate into DNA and form irreversible covalent bonds with DNA-methyltransferases at cytosine sites targeted for DNA methylation by increasing γ-globin expression through a posttranscriptional mechanism independent of DNA methylation. Decitabine has been shown substantial efficacy in reactivating epigenetically silenced tumor suppressor genes in vitro. In colon cancer cell lines, decitabine can increase the histone H3-lysine 9 acetylation: methylation ratio at the unmethylated hMLH1 and MGMT promoters in HCT116 and RKO cells, respectively. In T24 bladder cancer cells, decitabine can increase histone H3-lysine 9 acetylation and histone H3-lysine 4 methylation at the unmethylated p14 promoter.
30% Propylene glycol, 5% Tween 80, 65% D5W(5%葡萄糖水溶液)
0 -100 ng/mL
≤2.5 mg/kg 腹腔注射
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Shaker S, et al. Leuk Res, 2003, 27(5), 437-444.
[2] Zhu, W G., et al., 2001. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer research. 61(4): 1327-33.
[3] Takebayashi, S., et al., 2001. 5-Aza-2'-deoxycytidine induces histone hyperacetylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation. Biochemical and biophysical research communications. 288(4): 921-6.
[4] Jones, P A., et al., 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 20(1): 85-93.
分子式 C8H12N4O4 |
分子量 228.21 |
CAS号 2353-33-5 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 50 mg/mL |
Water 10 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT03045510 | Myelodysplastic Syndromes | Drug: decitabine | Shandong University | Phase 2 | 2016-12-01 | 2017-02-06 |
NCT01277484 | Myelodysplastic Syndrome|Acute Myeloid Leukemia | Drug: Decitabine | Seoul St. Mary's Hospital|Janssen, LP | Phase 1 | 2011-01-01 | 2015-11-18 |
NCT02316028 | Liver Metastasis|Colorectal Cancer | Drug: Decitabine | Universitair Ziekenhuis Brussel|Janssen, LP | Phase 1|Phase 2 | 2014-03-01 | 2016-09-14 |
NCT01251627 | Chronic Myelomonocytic Leukemia | Drug: Decitabine | Fondazione Italiana Sindromi Mielodisplastiche Onlus|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte | Phase 2 | 2010-04-01 | 2017-02-14 |
NCT01633099 | Untreated Adult Acute Myeloid Leukemia|Effect of Drugs|Drug Safety | Drug: Decitabine | Jianxiang Wang|Xian-Janssen Pharmaceutical Ltd.|Chinese Academy of Medical Sciences | Phase 3 | 2012-05-01 | 2012-07-04 |
NCT01568333 | Immune Thrombocytopenia | Drug: Decitabine | Shandong University|Qingdao University|Shandong Provincial Hospital | Phase 2 | 2015-06-01 | 2016-07-26 |
NCT00744757 | Myelodysplastic Syndrome | Drug: Decitabine | Johnson & Johnson Taiwan Ltd | Phase 2 | 2008-08-01 | 2013-08-26 |
NCT02252107 | Acute Myeloid Leukemia (AML) | Drug: decitabine | Radboud University | Phase 2 | 2014-10-01 | 2016-04-06 |
NCT02257138 | Leukemia|Myeloproliferative Diseases | Drug: Ruxolitinib|Drug: Decitabine | M.D. Anderson Cancer Center|Incyte Corporation | Phase 1|Phase 2 | 2015-02-01 | 2017-03-23 |
NCT00349596 | Acute Lymphocytic Leukemia | Drug: Decitabine | M.D. Anderson Cancer Center|Eisai Inc. | Phase 1 | 2006-07-01 | 2014-10-13 |
NCT03080766 | Acute Myeloid Leukemia|Complex Karyotype | Drug: Decitabine | The University of Hong Kong|Janssen, LP | Phase 2 | 2017-03-01 | 2017-03-09 |
NCT02141477 | Leukemia | Drug: Omacetaxine|Drug: Decitabine | M.D. Anderson Cancer Center|Teva Pharmaceuticals USA | Phase 2 | 2015-05-01 | 2016-12-06 |
NCT00477386 | Ovarian Cancer | Drug: decitabine | Indiana University|Eisai Inc. | Phase 1|Phase 2 | 2007-07-01 | 2014-09-19 |
NCT00414310 | Myelodysplastic Syndrome|Acute Myelogenous Leukemia | Drug: Decitabine|Drug: Valproic Acid | M.D. Anderson Cancer Center|Eisai Inc. | Phase 2 | 2006-12-01 | 2015-07-15 |
NCT00866073 | Acute Myeloid Leukemia | Drug: Decitabine 15 mg/m2 i.v. | University Hospital Freiburg | Phase 2 | 2003-04-01 | 2009-03-19 |
NCT02264873 | Leukemia, Lymphoblastic, Acute|Leukemia, Myeloid Acute|Hematopoetic Myelodysplasia | Drug: Decitabine | University of Florida | Phase 1 | 2014-10-01 | 2016-11-29 |
NCT01893320 | Leukemia | Drug: Vosaroxin|Drug: Decitabine | M.D. Anderson Cancer Center|Sunesis Pharmaceuticals | Phase 1|Phase 2 | 2013-07-18 | 2017-02-03 |
NCT02499861 | Cancer | Drug: Decitabine and Genistein | St. Justine's Hospital | Phase 1|Phase 2 | 2015-07-01 | 2016-05-08 |
NCT01687400 | Leukemia, Myeloid, Acute|Myelodysplastic Syndromes | Drug: decitabine | Washington University School of Medicine | Phase 2 | 2013-02-12 | 2017-01-26 |
NCT01786343 | Leukemia | Drug: Decitabine | M.D. Anderson Cancer Center | Phase 2 | 2013-02-01 | 2016-08-25 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们